|Articles|July 2, 2003
- Pharmaceutical Technology-07-02-2003
- Volume 27
- Issue 7
Understanding and Implementing a Risk-Based Approach to 21 CFR Part 11 Compliance
Pharmaceutical companies must take a holistic look at their systems and supporting processes to implement FDA's risk-based approach into their 21 CFR Part 11 complaince strategies.
Advertisement
Articles in this issue
about 23 years ago
July 2003about 23 years ago
The Push for Generics Challenges Manufacturersabout 23 years ago
Emerging Research Opportunities in Oral Inhalation Technologyabout 23 years ago
Preventing Metal Contaminationabout 23 years ago
Capacity Worries Fade for BiomanufacturingAdvertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
PharmTech Weekly Roundup–July 10, 2026
2
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
3
The FDA Moves to Modernize Drug Manufacturing Registration
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5